HCC Stock Recent News

This campaign aims to raise awareness of the high-quality care and services provided by Susan G. Komen to improve and save the lives of those impacted by breast cancer This campaign aims to raise awareness of the high-quality care and services provided by Susan G. Komen to improve and save the lives of those impacted by breast cancer

PITTSBURGH--(BUSINESS WIRE)-- #Innovation--Somerset International has successfully deployed six state-of-the-art Tailings Dewatering systems at Warrior Met Coal's Blue Creek Mine.

Thermal coal may retire for good in the U.S., but metallurgical coal could see “healthy” growth, says analyst.

MORRISTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it has entered into a binding letter of intent (“LOI”) with New Day Diagnostics LLC to in-license diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC). The celiac, respiratory multiplex and H. pylori tests have CE marks and are eligible to be sold in Europe at the present time.

Warrior Met Coal's strong margins and strategic location contribute to its resilience, with only a 12% stock price decline this year compared to peers' 30-40% drop. Q1 2025 results showed a weak performance, with $39M adjusted EBITDA and negative $68M free cash flow due to soft coking coal prices. Despite weak market conditions, Warrior's liquidity is robust with $617M available, ensuring coverage for Blue Creek's remaining capex and potential losses.

Warrior Met Coal, Inc. (NYSE:HCC ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Brian Chopin - Chief Accounting Officer and Controller Walter Scheller - Chief Executive Officer Dale Boyles - Chief Financial Officer Conference Call Participants Katja Jancic - BMO Capital Markets Nick Giles - B. Riley Securities George Eady - UBS Nathan Martin - The Benchmark Company Operator Good afternoon, my name is Dhawan, and I will be your conference operator today.

Warrior Met Coal (HCC) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $2.63 per share a year ago.

BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (NYSE: HCC) (“Warrior” or the “Company”) today announced results for the first quarter of 2025. Warrior is the leading dedicated U.S.-based producer and exporter of high-quality steelmaking coal for the global steel industry. Warrior reported a net loss for the first quarter of 2025 of $8.2 million, or $0.16 per diluted share, a decrease from net income of $137.0 million, or $2.62 per diluted share, in the first quarter of 2024. The Compa.

BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (NYSE:HCC) (“Warrior” or the “Company”) today announced that its board of directors has approved a regular quarterly cash dividend of $0.08 per share to be paid on May 12, 2025, to stockholders of record as of the close of business on May 5, 2025. About Warrior Warrior is a U.S.-based, environmentally, and socially minded supplier to the global steel industry. It is dedicated entirely to mining non-thermal metallurgical (met) coal used as.

Warrior Met Coal (HCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.